Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 4, 2002, Pages 467-475

  Wang, Liang Shun ^a   Chow, K C ^a   Wu, Y C ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cyclooxygenase; Esophageal carcinoma; Inflammation

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; BUTYRIC ACID; CYCLOOXYGENASE 2; ETODOLAC; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C INHIBITOR; RECOMBINANT INTERLEUKIN 6; SAFINGOL; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTYRATES; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0036207397     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655202317316114     Document Type: Article

References (44)

1. Surgical treatment of esophageal carcinoma
2. Prognosis of esophageal squamous cell carcinoma - Analysis of clinicopathological and biological factors
3. Precursor lesions of esophageal cancer in high-risk populations in Iran and China
4. Precursor lesions of esophageal cancer in low-risk population in China: Comparison with high-risk populations
5. Aspirin and reduced risk of esophageal carcinoma
6. Aspirin use and risk of fatal cancer
7. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
8. Inhibition of cyclooxygenase: A novel approach to cancer prevention
9. Prostaglandin endoperoxide synthase: Structure and catalysis
10. Human cyclooxygenase-2 cDNA
11. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes
12. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1β, phorbol ester, and corticosteroids
13. Prostaglandin synthase 2
14. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
15. Cyclooxygenase-2 gene expression in human breast cancer
16. Expression of cyclooxygenase-2 in human lung carcinoma
17. Expression of cyclooxygenase-2 in human gastric carcinoma
18. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
19. Cyclooxygenase-2 expression in human esophageal carcinoma
20. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
21. Prostaglandins from tumours of human large bowel
22. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo
23. Cyclooxygenase gene expression in inflammation and angiogenesis
24. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters
25. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate
26. The structure and function of platelet-activating factor acetylhydrolases
27. Release of platelet-activating factor in human leukemia
28. Human cyclooxygenase-2 cDNA
29. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog
30. Adenovirus infection elevates levels of cellular topoisomerase I
31. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
32. Immunocytochemical localization of cyclo-oxygenase isoforms in cultured human airway structural cells
33. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation
34. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells
35. Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes
36. Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils
37. Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: Novel inflammatory role of this cell type
38. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway
39. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline
40. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways
41. On the induction of cyclooxygenase-2, inducible nitric oxide synthase and soluble phospholipase A2 in rat mesangial cells by a nonsteroidal anti-inflammatory drug: The role of cyclic AMP
42. Platelet-activating factor and platelet-activating factor antagonists in acute pancreatitis
43. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
44. The role of Epstein-Barr virus infection and the immunocompetence of patients with nasopharyngeal cancers